PRA-216 compared with placebo in people with COPD and type 2 inflammation
Tests the safety of PRA-216 in adults with chronic obstructive pulmonary disease.
Plain-language title generated from the registry record
Registry title: PRA-216 COPD Safety and Biomarker Study
Key facts
- Where
- Birtinya, Botany, Camberwell, Campbelltown, and Southport, AustraliaSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07730281, who can take part
Where in Australia
- University of the Sunshine CoastBirtinya, AustraliaTaking people
- Emeritus Research SydneyBotany, AustraliaTaking people
- Emeritus Research CamberwellCamberwell, AustraliaTaking people
- Campbelltown HospitalCampbelltown, AustraliaNot yet recruiting
- Griffith UniversitySouthport, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prana Therapies Inc
- Trial code
- NCT07730281
- Record updated
- 28 October 2026
- Original description
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).Read full original descriptionShow less
A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Inclusion: Age 40-80; Willing and able to attend all study visits, comply with study requirements; Able and willing to provide written informed consent; Documented COPD diagnosis prior for at least 12 months prior to screening; Currently receiving maintenance COPD medications at a stable dose for at least 3 months prior to visit 1.
Exclusion: Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent; Major surgery occurring within 8 weeks months prior to first dose of investigational product; Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1; Evidence of clinically significant pulmonary condition or disease other than COPD; Any physical or psychological condition that prohibits study completion; History of severe allergic reactions or hypersensitivity.